This article is more than 5 years old. Information may no longer be current.
Choroidal thickness may remain unaffected by anti-VEGFs in neovascular AMD cases
Click Here to Manage Email Alerts
 SriniVas Sadda |
BOSTON — Intravitreal anti-VEGF therapy may not affect choroidal thickness in patients with neovascular age-related macular degeneration, a presentation here suggested.
"Choroidal thickness did appear to decrease slightly over time in eyes with neovascular AMD, but it was reassuring to us to see that intravitreal anti-VEGF therapy at least did not appear to accelerate or otherwise alter this decline," SriniVas Sadda, MD, said at the American Society of Retina Specialists meeting.
Sixty eyes of 47 patients with fully visible choroids were included in the retrospective analysis. Mean follow-up was 23.8 months, and eyes in the treatment group received an average of 7.8 injections. Subfoveal choroidal thickness was evaluated from Bruch's membrane to the choroidal-sclera junction using spectral domain optical coherence tomography.
Subfoveal choroidal thickness at baseline was 126.7 µm in the untreated group and 136.2 µm in the treated group, and average reduction did not differ significantly between the two groups.
The authors acknowledged study design and small sample size as limitations and also suggested that future studies maximize choroidal visualization using upcoming long-wavelength OCT technology.
- Disclosure: Dr. Sadda is a consultant for Heidelberg Engineering and receives research support from Carl Zeiss Meditec, Optovue and Optos. He also previously shared in royalties from intellectual property licensed by Doheny to Topcon Medical Systems.